Restoring Sight | Reclaiming Lives

BostonSight® is a world renowned nonprofit eye health care organization. Our mission is to improve quality of life by transforming the understanding, treatment and care of the ocular surface. Since 1992, we have restored sight to thousands of patients from around the world.

Our Needham, MA Center of Excellence includes a Medical Institute, a Research Center, a state-of-the-art Manufacturing Lab, and a Patient and Family Support Center. Compassionate care is at the heart of our approach to medicine.

BostonSight PROSE Treatment

BostonSight PROSE (prosthetic replacement of the ocular surface ecosystem) is a medical treatment pioneered by BostonSight that restores visual function, supports healing, reduces symptoms, and improves quality of life for patients suffering with complex corneal disease. Using FDA approved (1994) custom designed and fabricated prosthetic devices to replace or support impaired ocular surface system functions, BostonSight PROSE is available at top-ranked academic medical centers and clinics across the U.S. through the BostonSight Network

Find out if BostonSight PROSE treatment can help you.

BostonSight SCLERAL

BostonSight SCLERAL is our new (2017) data driven, FDA-cleared innovative product, delivering doctors and patients unparalleled scleral lens design. BostonSight SCLERAL is the first scleral lens fitting system based on scleral anatomy, driven by clinical data, and the first with front surface eccentricity options to improve both quantitative and qualitative vision. 

Learn more about BostonSight SCLERAL and find a practitioner.

Latest News 

Sign up for email delivery of our e-bulletin.

  Read Transforming Lives - Our 2017 annual report

  scheduling is now available through email at

  Email us today to schedule your next appointment

Introducing BostonSight SCLERAL

BostonSight recently launched BostonSight SCLERAL, a new vision for irregular cornea and ocular surface disease. BostonSight SCLERAL lenses are available at more than 100 locations in 25 states and Puerto Rico, with more being added each week.